MA53490A - Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire - Google Patents
Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaireInfo
- Publication number
- MA53490A MA53490A MA053490A MA53490A MA53490A MA 53490 A MA53490 A MA 53490A MA 053490 A MA053490 A MA 053490A MA 53490 A MA53490 A MA 53490A MA 53490 A MA53490 A MA 53490A
- Authority
- MA
- Morocco
- Prior art keywords
- kallicrein
- odema
- attack
- inhibitors
- plasma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725216P | 2018-08-30 | 2018-08-30 | |
| US201962808612P | 2019-02-21 | 2019-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53490A true MA53490A (fr) | 2022-05-04 |
Family
ID=67953889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053490A MA53490A (fr) | 2018-08-30 | 2019-08-30 | Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200109214A1 (fr) |
| EP (1) | EP3843840A1 (fr) |
| JP (1) | JP2021535161A (fr) |
| KR (1) | KR20210053928A (fr) |
| CN (1) | CN113056304A (fr) |
| AU (1) | AU2019328324A1 (fr) |
| BR (1) | BR112021003789A2 (fr) |
| CA (1) | CA3110689A1 (fr) |
| IL (1) | IL281063A (fr) |
| MA (1) | MA53490A (fr) |
| MX (1) | MX2021002349A (fr) |
| WO (1) | WO2020047352A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| CN105051068A (zh) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
| CN106459210A (zh) | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
| EA201891388A1 (ru) | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека |
| CA3167336A1 (fr) * | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la kallicreine plasmatique et leurs utilisations pour traiter une crise d'angio-deme hereditaire pediatrique |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DK0739355T3 (da) | 1994-01-11 | 2005-01-24 | Dyax Corp | Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JP2005534647A (ja) | 2002-06-07 | 2005-11-17 | ダイアックス、コープ | 失血の予防及び軽減 |
| CN103635489B (zh) * | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
| CN105051068A (zh) * | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
| CN106459210A (zh) * | 2014-03-27 | 2017-02-22 | 戴埃克斯有限公司 | 用于治疗糖尿病黄斑性水肿的组合物和方法 |
| WO2016160926A1 (fr) * | 2015-03-30 | 2016-10-06 | Dyax Corp. | Inhibiteurs de la kallicréine plasmatique et utilisations desdits inhibiteurs pour prévenir un accès d'angio-oedème héréditaire |
| EA201891388A1 (ru) * | 2015-12-11 | 2018-11-30 | Дайэкс Корп. | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека |
| CN108368840B (zh) * | 2015-12-18 | 2020-10-09 | 固瑞克明尼苏达有限公司 | 波纹管安装及保持方法 |
-
2019
- 2019-08-30 EP EP19768977.1A patent/EP3843840A1/fr active Pending
- 2019-08-30 CA CA3110689A patent/CA3110689A1/fr active Pending
- 2019-08-30 KR KR1020217009365A patent/KR20210053928A/ko active Search and Examination
- 2019-08-30 WO PCT/US2019/048961 patent/WO2020047352A1/fr unknown
- 2019-08-30 JP JP2021510984A patent/JP2021535161A/ja active Pending
- 2019-08-30 MA MA053490A patent/MA53490A/fr unknown
- 2019-08-30 AU AU2019328324A patent/AU2019328324A1/en active Pending
- 2019-08-30 MX MX2021002349A patent/MX2021002349A/es unknown
- 2019-08-30 CN CN201980072190.9A patent/CN113056304A/zh active Pending
- 2019-08-30 BR BR112021003789-6A patent/BR112021003789A2/pt unknown
- 2019-08-30 US US16/556,524 patent/US20200109214A1/en not_active Abandoned
-
2021
- 2021-02-23 IL IL281063A patent/IL281063A/en unknown
-
2022
- 2022-05-16 US US17/745,770 patent/US20230104754A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230104754A1 (en) | 2023-04-06 |
| CA3110689A1 (fr) | 2020-03-05 |
| US20200109214A1 (en) | 2020-04-09 |
| JP2021535161A (ja) | 2021-12-16 |
| IL281063A (en) | 2021-04-29 |
| KR20210053928A (ko) | 2021-05-12 |
| BR112021003789A2 (pt) | 2021-05-18 |
| EP3843840A1 (fr) | 2021-07-07 |
| CN113056304A (zh) | 2021-06-29 |
| WO2020047352A1 (fr) | 2020-03-05 |
| AU2019328324A1 (en) | 2021-04-29 |
| MX2021002349A (es) | 2021-05-31 |
| WO2020047352A8 (fr) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53490A (fr) | Inhibiteurs de la kallicréine plasmatique et leurs utilisations pour traiter une crise d'angio-odème héréditaire | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| CY1121653T1 (el) | C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης | |
| PH12018502046A1 (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
| MA51208A (fr) | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer | |
| EA201792161A1 (ru) | Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека | |
| MA44990A (fr) | Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1 | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
| MA45025A (fr) | Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1 | |
| IL259691A (en) | Plasma kallikrein inhibitors and their uses for the treatment of hereditary angioedema attack | |
| MA44878A (fr) | Anticorps anti-facteur bb du complément et utilisations de ceux-ci | |
| ITUB20155056A1 (it) | Metodo per l'identificazione e la prevenzione di attacchi web lato client | |
| FR3017443B1 (fr) | Enceinte isolee et procede de balayage d'une telle enceinte | |
| FR3048094B1 (fr) | Interface pour aeronef et procede de commande d'une telle interface | |
| MA49684A (fr) | Arnm modifié codant une glucose-6-phosphatase et utilisations associées | |
| WO2017059122A8 (fr) | Méthodes de traitement et de prévention d'une sclérose latérale amyotrophique | |
| IL285352A (en) | Anti-nme antibody and method for treating cancer or cancer metastases | |
| MA56213A (fr) | Développement d'inhibiteurs catalytiques de hdac3 et leurs utilisations | |
| MA52202A (fr) | Compositions d'érénumab et utilisations de celles-ci | |
| MA52247A (fr) | Conjugués phospholipide-flavagline et procédés d'utilisation de ceux-ci pour une thérapie anticancéreuse ciblée |